MBX · CIK 1776111
What MBX Biosciences, Inc. told the SEC could break it.
MBX's disclosures cluster on the supply chain behind its drug development and the policy that could shape its future pricing. Its inputs are strained on two fronts: a global shortage of non-human primates (cynomolgus monkeys), worsened by reduced China exports, has sharply raised the price of a critical research model, while its product candidates depend on APIs and raw materials exposed to China-based suppliers, U.S. tariffs and possible Chinese retaliation. It also outsources all manufacturing — API and final drug product — to third-party CMOs, with no in-house capability. Looking ahead, it flags CMS's December 2025 GLOBE and GUARD proposals, which would tie federal drug reimbursement to international most-favored-nation benchmark prices and expose future products to mandatory rebates.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Commodity & input dependence
- Non-human primate (cynomolgus monkey) research modelsmedium
Constrained global supply of non-human primates (cynomolgus monkeys) for preclinical research, following reduced China exports, has driven scarcity and sharply higher pricing for a critical research model.
“This change in the world supply of a critical research model has resulted in increased demand from breeding farms principally located in Cambodia, Vietnam, and Mauritius Island, with a resultant marked increase in unit pricing.”
SEC filing →As of 2026 - China-sourced APIs and raw materialsmedium
MBX's product candidates rely on APIs and raw materials exposed to China-based suppliers, U.S. tariffs on imports, and potential Chinese retaliatory trade measures.
“further tariffs may be imposed that could affect imports of APIs used in our product candidates, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to such raw materials used in our product candidates.”
Regulatory & policy
- CMS Most-Favored-Nation drug-pricing proposals (GLOBE/GUARD)medium
CMS's December 2025 GLOBE (Part B) and GUARD (Part D) proposed rules would tie federal drug reimbursement to international MFN benchmark prices, exposing future MBX products to mandatory rebates.
“On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs.”
SEC filing →As of 2026
Supplier concentration
- Outsourced third-party API and drug-product manufacturingmedium
MBX outsources all manufacturing of its product candidates (API and final drug product) to third-party CMOs and has no in-house manufacturing capability.
“Our current strategy is to outsource all manufacturing of our product candidates to third parties. We currently rely on and engage third-party manufacturers to provide all of the API and the final drug product formulation of all of our product candidates that are being used in our clinical trials and preclinical studies.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch